Extra-gastrointestinal stromal tumors (EGISTs): A case report for a mischief entity. Issue 13 (31st March 2023)

• Record Type: Journal Article
• Authors: El Charif, Mohamad Hadi; Amro, Sara; Boulos, Fouad; Khalife, Mohamad; Shamseddine, Ali; Assi, Hazem; Sbaity, Eman
• Is Part Of: Medicine. Volume 102:Issue 13(2023)
• Page Start: e33394
• Publication Date: 2023-03-31
• Subjects: case report -- EGIST -- extra-gastrointestinal stromal tumor -- histology -- soft tissue sarcoma -- subtype; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000033394
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Background: Extra-gastrointestinal stromal tumor is a rare subtype of soft tissue sarcomas with significantly variable presentation, management, and prognosis. This makes it crucial to report the different institutional experiences of encountering extra-gastrointestinal stromal tumors (EGIST). Case presentation: We report 3 cases of EGIST diagnosis at American University of Beirut Medical Center for 2 males and 1 female in the 5th, 6th, and 7th decades of life, respectively. For the first case, the tumor was initially suspected to be ovarian cancer, but biopsy revealed a diagnosis of EGIST, and the patient was started on neoadjuvant therapy. In the second case, the tumor was retro-gastric and prelim diagnosis was gastric cancer but again biopsy revealed an EGIST histopathology, and the patient underwent surgery and adjuvant treatment. For the third case, a previous history of testicular cancer prompted an initial suspicion of recurrence with metastasis but biopsy and immunohistochemistry staining revealed EGIST with related markers. The patient underwent treatment at a different institution in his home country. Conclusion: This report sheds light on the importance of keeping EGIST amongst any differential list for abdominal and pelvic tumors. It also shows that EGIST-focused studies are needed to assess the effectiveness of the different treatment modalities available when utilized specifically for EGIST. This would allow for better oncological outcomes and improved quality of life.